Rivaroxaban for stroke prevention in east Asian patients from the ROCKET AF trial

Stroke

Volumn 45, Issue 6, 2014, Pages 1739-1747

  Wong, Ka Sing Lawrence ^a   Hu, Dai Yi ^b   Oomman, Abraham ^c   Tan, Ru San ^d   Patel, Manesh R ^e   Singer, Daniel E ^g   Breithardt, Günter ^h   Mahaffey, Kenneth W ^e   Becker, Richard C ^e   Califf, Robert ^f   Fox, Keith A A ⁱ   Berkowitz, Scott D ^j   Hacke, Werner ^k   Hankey, Graeme J ^l  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^c APOLLO HOSPITALS   (India)

^d DEPARTMENT OF CARDIOLOGY   (Singapore)

^e DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^j BAYER CORPORATION   (United States)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

more..

Author keywords

atrial fibrillation; Far East; rivaroxaban; stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; RIVAROXABAN; WARFARIN;

ARTICLE; ASIAN; BLEEDING; BODY MASS; BODY WEIGHT; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; EMBOLISM PREVENTION; FAR EAST; FEMALE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY (TOPIC); PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

ATRIAL FIBRILLATION; FAR EAST; RIVAROXABAN; STROKE;

AGED; ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; FACTOR XA; FAR EAST; FEMALE; HUMANS; MALE; MORPHOLINES; RISK FACTORS; STROKE; THIOPHENES; VITAMIN K; WARFARIN;

EID: 84901924970     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.002968     Document Type: Article

References (29)

1. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fbrillation. N Engl J Med. 2011;365:883-891.
2. Wang D, Li Y, Lee SG, Wang L, Fan J, Zhang G, et al. Ethnic differences in body composition and obesity related risk factors: study in Chinese and white males living in China. PLoS One. 2011;6:e19835.
3. Thrift AG, Dewey HM, Macdonell RA, McNeil JJ, Donnan GA. Incidence of the major stroke subtypes: initial fndings from the North East Melbourne stroke incidence study (NEMESIS). Stroke. 2001;32:1732-1738.
4. Zhang LF, Yang J, Hong Z, Yuan GG, Zhou BF, Zhao LC, et al; Collaborative Group of China Multicenter Study of Cardiovascular Epidemiology. Proportion of different subtypes of stroke in China. Stroke. 2003;34:2091-2096.
5. Ng WK, Goh KJ, George J, Tan CT, Biard A, Donnan GA. A comparative study of stroke subtypes between Asians and Caucasians in two hospital-based stroke registries. Neurol J Southeast Asia. 1998;3:19-26.
6. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, et al. Novel CYP2C9 genetic variants in Asian subjects and their infuence on maintenance warfarin dose. Clin Pharmacol Ther. 2004;76:210-219.
7. Yuen E, Gueorguieva I, Wise S, Soon D, Aarons L. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin. J Pharmacokinet Pharmacodyn. 2010;37:3-24.
8. Fugh-Berman A. Herb-drug interactions. Lancet. 2000;355:134-138.
9. Shen AY, Yao JF, Brar SS, Jorgensen MB, Chen W. Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fbrillation. J Am Coll Cardiol. 2007;50:309-315.
10. Shen AY, Chen W, Yao JF, Brar SS, Wang X, Go AS. Effect of race/ethnicity on the effcacy of warfarin: potential implications for prevention of stroke in patients with atrial fbrillation. CNS Drugs. 2008;22:815-825.
11. Wen-Hang QI; Society of Cardiology, Chinese Medical Association. Retrospective investigation of hospitalised patients with atrial fbrillation in mainland China. Int J Cardiol. 2005;105:283-287.
12. Gao Q, Fu X, Wei JW, Chen X, Huang Y, Wang J, et al; China QUEST Study Investigators. Use of oral anticoagulation among stroke patients with atrial fbrillation in China: the ChinaQUEST (Quality evaluation of stroke care and treatment) registry study. Int J Stroke. 2013;8:150-154.
13. Huang CX, Zhang S, Ma CS, Yang YZ, Huang DJ, Cao KJ, et al. Current knowledge and management recommendations of atrial fbrillation. Chin J Cardiac Arrhythmia. 2010;14:328-369.
14. ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010;159:340-347.e1.
15. Atarashi H, Inoue H, Okumura K, Yamashita T, Kumagai N, Origasa H; J-RHYTHM Registry Investigators. Present status of anticoagulation treatment in Japanese patients with atrial fbrillation: a report from the J-RHYTHM Registry. Circ J. 2011;75:1328-1333.
16. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fbrilla-tion-the J-ROCKET AF study. Circ J. 2012;76:2104-2111.
17. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69:236-239.
18. Mueck W, Eriksson BI, Bauer KA, Borris L, Dahl OE, Fisher WD, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008;47:203-216.
19. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited infuence on the safety, tolerability, pharmacokinetics, or pharma-codynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol. 2007;47:218-226.
20. Kim AS, Johnston SC. Global variation in the relative burden of stroke and ischemic heart disease. Circulation. 2011;124:314-323.
21. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A, et al; ROCKET AF Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fbrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012;11:315-322.
22. You JH, Chan FW, Wong RS, Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation? Br J Clin Pharmacol. 2005;59:582-587.
23. Chang YJ, Ryu SJ, Chen JR, Hu HH, Yip PK, Chiu TF; Consensus Group of Taiwan Stroke Society. [Guidelines for the general management of patients with acute ischemic stroke]. Acta Neurol Taiwan. 2008;17:275-294.
24. Korean Clinical Research Center for Stroke. Clinical Practice Guidelines for Stroke. 2010. http://www.stroke-crc.or.kr/cpgs%20for%20stroke%20 (english).pdf. Accessed January 1, 2011.
25. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fbrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
26. You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al; American College of Chest Physicians. Antithrombotic therapy for atrial fbrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 suppl):e531S-e575S.
27. Garcia DA, Lopes RD, Hylek EM. New-onset atrial fbrillation and warfarin initiation: high risk periods and implications for new antithrom-botic drugs. Thromb Haemost. 2010;104:1099-1105.
28. Hori M, Connolly SJ, Zhu J, Liu LS, Lau CP, Pais P, et al; RE-LY Investigators. Dabigatran versus warfarin: effects on ischemic and hem-orrhagic strokes and bleeding in Asians and non-Asians with atrial fbril-lation. Stroke. 2013;44:1891-1896.
29. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fbrillation. N Engl J Med. 2013;369:2093-2104.